Lenzing's Heiligenkreuz Site Gets a Longer Runway as 30 Suitors Circle
Published on 10/23/2026 at 10:11 | Editorial boerse-global.de
Lenzing has bought itself time on two fronts, and investors would do well to keep the two apart. The Austrian fibre maker has closed a rights issue that raises fresh capital, while simultaneously pushing back the shutdown of its Heiligenkreuz plant — a delay rooted in production logistics rather than any retreat from the restructuring plan.
The cash is in, the share count is up
The capital increase, reported as completed on Wednesday, generated gross proceeds of EUR 301.2 million, according to Reuters. Shares were priced at EUR 8.65 apiece, and 99.0% of the offer was subscribed through subscription rights. The consortium banks sold any unsubscribed stock on the open market.
Lenzing intends to use the proceeds to shore up its capital structure and bankroll its "Grow Nonwovens, Reset Textiles" strategy. The flip side is dilution: 34,756,362 new shares were issued, and once the announced inclusion takes effect, the total share count will reach 73,374,542 — roughly double the prior base. Existing holders therefore get both a better-capitalised company and a smaller slice of it.
Heiligenkreuz slips to the first quarter of 2027
The operational story looks rather different. Media reports indicate the Heiligenkreuz facility will now cease production at the end of the first quarter of 2027, rather than at the end of 2026 as originally planned. Around 285 employees are affected.
Should investors sell immediately? Or is it worth buying Lenzing?
Lenzing attributes the delay to the transfer of production to other sites and the need to keep customers supplied during the transition. The timeline thus hinges not on the closure decision itself but on how smoothly manufacturing can be picked up elsewhere. A plant cannot be wound down by the calendar alone.
Roughly 30 interested parties are currently in contact with Lenzing about a possible takeover of the site, a company spokesperson said. Those talks open an additional avenue for Heiligenkreuz, though interest is not the same as an agreed sale.
Two problems, two clocks
Fresh equity and a production relocation solve different problems, and conflating them misreads the investment case. The financing provides the means for the chosen path; the site transition demands execution on the ground. A 99% take-up is an outcome of the capital raise — it says nothing about whether the operational test will be passed.
Lenzing at a turning point? This analysis reveals what investors need to know now.
Nor should the later shutdown be read as a reversal of the site decision or as proof the turnaround is working. What it does show is the task still ahead: production must be absorbed elsewhere while customers continue to be served. The extra time is not automatically a negative — its value depends on whether it serves the stated purpose of protecting supply through the handover.
For anyone tracking the equity, Heiligenkreuz is the more concrete yardstick for the promised transformation. Not because a single site captures the whole strategy, but because it exposes what the strategy demands in practice: relocated output and uninterrupted customer service, delivered together. The reliable progress so far sits on the financing side. On the operational side, the shifted schedule and the takeover discussions remain the tangible markers to watch.
Ad
Lenzing Stock: New Analysis - 23 October
Fresh Lenzing information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
